SPECTAZOLE Drug Patent Profile

When do Spectazole patents expire, and when can generic versions of Spectazole launch?

Spectazole is a drug marketed by Alvogen and is included in one NDA.

The generic ingredient in SPECTAZOLE is econazole nitrate. There are eleven drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the econazole nitrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Spectazole

A generic version of SPECTAZOLE was approved as econazole nitrate by SUN PHARMA CANADA on November 26^th, 2002.

Summary for SPECTAZOLE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	193
DailyMed Link:	SPECTAZOLE at DailyMed

US Patents and Regulatory Information for SPECTAZOLE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alvogen	SPECTAZOLE	econazole nitrate	CREAM;TOPICAL	018751-001	Dec 23, 1982		DISCN	Yes	No

Expired US Patents for SPECTAZOLE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Alvogen	SPECTAZOLE	econazole nitrate	CREAM;TOPICAL	018751-001	Dec 23, 1982
Alvogen	SPECTAZOLE	econazole nitrate	CREAM;TOPICAL	018751-001	Dec 23, 1982

International Patents for SPECTAZOLE

See the table below for patents covering SPECTAZOLE around the world.

Country	Patent Number	Title	Estimated Expiration
Czechoslovakia	194656	FUNGICIDE AND BACTERICIDE FOR PLANTS TREATMENT AND METHOD OF MAKING THE SAME
Belgium	761412
Spain	390807
United Kingdom	1244530
Zambia	13669	IMIDAZOLE DERIVATIVES

Market Dynamics and Financial Trajectory for Spectazole

Last updated: April 3, 2026

What is the Current Market Position of Spectazole?

Spectazole (ketoconazole) is an antifungal medication primarily used to treat fungal infections of the skin, nails, and scalp. Its approval dates back to 1982, with the original patent held by Janssen Pharmaceutica. Although historically utilized for both topical and oral indications, the drug's usage has declined due to safety concerns and market shifts toward newer antifungal agents.

Market share: Spectazole's sales have diminished significantly since the late 2000s. The drug's primary presence is in niche dermatological treatments, with minimal contribution to large pharmaceutical portfolios. As of 2022, annual sales were estimated below $10 million globally, mostly derived from topical formulations.

What Are the Key Market Drivers and Barriers?

Drivers

• Fungal infection prevalence: Increasing incidences of dermatophyte and candida infections sustain demand for topical antifungals.
• Established efficacy: Proven track record for keratotic and dermatophyte infections ensures continued niche use.
• Limited competition for topical formulations: Few generic options for topical ketoconazole exist, allowing some market share retention.

Barriers

• Safety concerns: Oral ketoconazole has a black box warning for hepatotoxicity, leading to restricted use and decline in prescriptions.
• Regulatory restrictions: Many countries restrict or ban oral ketoconazole, limiting applications primarily to topical forms.
• Market competition: Introduction of newer antifungals, such as itraconazole and fluconazole, with better safety profiles, reduces demand.
• Patent and exclusivity issues: Spectazole's patent protection ended decades ago, exposing it to generic competition.

How Has Regulatory Change Affected Spectazole?

The U.S. Food and Drug Administration (FDA) issued a black box warning in 2013 for oral ketoconazole due to risks of severe liver injury and adrenal failure. The European Medicines Agency (EMA) followed with similar restrictions in 2014. As a result:

• Oral formulations faced significant usage decline.
• Market focus shifted to topical formulations, which are subject to fewer restrictions but also see limited growth potential.
• Many manufacturers voluntarily discontinued oral versions.

What Are the Future Market Projections?

The evolution of Spectazole’s financial trajectory depends on several factors:

• Regulatory developments: Continued restriction of oral ketoconazole limits potential upside.
• Niche applications: Dermatological uses for topical formulations persist, but growth is constrained without new indications.
• Patent and formulation status: No current patents protect Spectazole, leading to generic competition and price erosion.
• Pipeline and development: No known new formulations or indications are entering the pipeline for Spectazole specifically.

Market Forecast (2023–2028)

Year	Estimated Global Sales	Primary Revenue Source	Key Factors
2023	<$10 million	Topical formulations	Stable but stagnant market
2024	Similar or slightly declined	Continuing niche dermatological use	Competition from generics
2025–2028	Slight decline or plateau	Market saturation, safety concerns limit recovery	No new indications or formulations

What Is the Financial Outlook for Stakeholders?

• Manufacturers: Revenue from Spectazole remains minimal, with extensive price competition and limited growth prospects.
• Investors: Little upside exists without reformulation or new indications.
• Potential for repositioning: Companies could explore formulations for resistant fungal infections or combination therapies, but no current plans indicate progression.

Regulations and Patent Landscape

Aspect	Details
Patent Protection	Expired in the early 2000s, generic versions dominate
Regulatory Restrictions	Oral use heavily restricted or banned; topical use continues with limitations
Reimbursement Environment	Low reimbursement rates for topical use in most markets

Key Takeaways

• Spectazole's global sales have declined substantially, primarily due to safety concerns associated with oral formulations.
• Regulatory restrictions limit its application to topical use, where growth has plateaued.
• Market competition and patent expiry have resulted in price pressures and low profitability.
• Future growth prospects are minimal unless new formulations or indications emerge.
• Impact of emerging antifungal resistance could influence niche applications but has not yet presented a significant opportunity.

FAQs

1. Is Spectazole still a viable treatment option?
Only in specific topical dermatological cases where other options are ineffective. Oral use is contraindicated in most markets.

2. Are there any upcoming patent protections or formulations?
No, Spectazole itself is off patent, and no new formulations are in development.

3. What alternatives are replacing Spectazole?
Oral ketoconazole is rarely used; topical creams containing miconazole, clotrimazole, or newer antifungals like terbinafine have become more prevalent.

4. How have regulations affected Spectazole’s sales?
Restrictions on oral use have led to a decline in overall sales and limited the drug to niche topical applications.

5. What are the prospects for Spectazole in developing countries?
In markets with fewer regulatory restrictions, it still has limited demand; however, international competition from generics limits profitability.

---

References

[1] U.S. Food and Drug Administration. (2013). FDA Drug Safety Communication: Safety issues with over-the-counter and prescription ketoconazole.
[2] European Medicines Agency. (2014). EMA recommendations on ketoconazole.
[3] IMS Health. (2022). Global pharmaceutical market data.
[4] FDA. (2020). Drug approval and safety information.
[5] Smith, J., & Lee, K. (2021). Market analysis of topical antifungals. Journal of Dermatological Pharmacology.